Erratum to “Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-KB signaling pathways”
The authors regret that the original paper listed an incorrect affiliation for the author Mohd Nazam Ansari. The correct affiliation is presented above..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:71 |
|---|---|
| Enthalten in: |
Pharmacological reports - 71(2019), 6 vom: Nov., Seite 1227-1227 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Imam, Faisal [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
© Maj Institute of Pharmacology Polish Academy of Sciences 2019 |
|---|
| doi: |
10.1016/j.pharep.2019.06.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR038904225 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR038904225 | ||
| 003 | DE-627 | ||
| 005 | 20230816064700.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.pharep.2019.06.009 |2 doi | |
| 035 | |a (DE-627)SPR038904225 | ||
| 035 | |a (SPR)j.pharep.2019.06.009-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Imam, Faisal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Erratum to “Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-KB signaling pathways” |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Maj Institute of Pharmacology Polish Academy of Sciences 2019 | ||
| 520 | |a The authors regret that the original paper listed an incorrect affiliation for the author Mohd Nazam Ansari. The correct affiliation is presented above. | ||
| 700 | 1 | |a Al-Harbi, Naif O. |4 aut | |
| 700 | 1 | |a Al-Harbi, Mohammad Matar |4 aut | |
| 700 | 1 | |a Ansari, Mushtaq Ahmad |4 aut | |
| 700 | 1 | |a Al-Asmari, Abdullah F. |4 aut | |
| 700 | 1 | |a Ansari, Mohd Nazam |4 aut | |
| 700 | 1 | |a Al-Anazi, Wael A. |4 aut | |
| 700 | 1 | |a Bahashwan, Saleh |4 aut | |
| 700 | 1 | |a Almutairi, Mashal M. |4 aut | |
| 700 | 1 | |a Alshammari, Musaad |4 aut | |
| 700 | 1 | |a Rashid Khan, Mohammad |4 aut | |
| 700 | 1 | |a Alsaad, Abdulaziz Mohammed |4 aut | |
| 700 | 1 | |a Alotaibi, Moureq Rashed |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacological reports |d Heidelberg : Springer Nature, 1998 |g 71(2019), 6 vom: Nov., Seite 1227-1227 |w (DE-627)SPR038875861 |w (DE-600)2129019-2 |x 2299-5684 |7 nnns |
| 773 | 1 | 8 | |g volume:71 |g year:2019 |g number:6 |g month:11 |g pages:1227-1227 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1016/j.pharep.2019.06.009 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 71 |j 2019 |e 6 |c 11 |h 1227-1227 | ||